Sight Sciences Inc (SGHT) Stock AnalysisSGHTSight Sciences Inc

Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Sight Sciences Inc is currently not a strong buy due to its recent price drop and negative earnings, despite some positive catalysts. The current price is $8.28, and the RSI is at 40.76, indicating it is nearing oversold territory but not quite there yet. The forward P/E is currently not applicable, and the gross margin is strong at 90.96%, but the company is still reporting significant net losses, with a net income of -4.446 million in Q2 2026. The main risk is the negative earnings trend, with a net margin of -19.01% in Q2 2026, which could impact investor sentiment moving forward.